QSAM Biosciences EV / EBITDA
Was ist das EV / EBITDA von QSAM Biosciences?
EV / EBITDA von QSAM Biosciences, Inc. ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf OTC im Vergleich zu QSAM Biosciences
Was macht QSAM Biosciences?
QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.
Unternehmen mit ev / ebitda ähnlich QSAM Biosciences
- ReNu hat EV / EBITDA von N/A
- Else Nutrition hat EV / EBITDA von N/A
- Bryah Resources hat EV / EBITDA von N/A
- Comtec Solar Systems hat EV / EBITDA von N/A
- DaFa Properties hat EV / EBITDA von N/A
- Electric Royalties hat EV / EBITDA von N/A
- QSAM Biosciences hat EV / EBITDA von N/A
- Identillect Technologies hat EV / EBITDA von N/A
- Kingland hat EV / EBITDA von N/A
- Theta Gold Mines hat EV / EBITDA von N/A
- Redfin Corp hat EV / EBITDA von N/A
- Nanollose hat EV / EBITDA von N/A
- Strike Resources hat EV / EBITDA von N/A